Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Blue Water Ventures International Inc (OP: BWVI ) 0.0018 UNCHANGED Streaming Delayed Price Updated: 9:30 AM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Blue Water Ventures International Inc Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences May 16, 2024 Via ACCESSWIRE Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space January 17, 2024 Via ACCESSWIRE Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc. December 12, 2023 Via ACCESSWIRE Psycheceutical Bioscience Launches Wefunder Crowdfunding Campaign for Safer Psychedelic Dosing November 01, 2023 Via ACCESSWIRE Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD August 10, 2023 Via ACCESSWIRE Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy August 01, 2023 Via ACCESSWIRE First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD July 13, 2023 Via ACCESSWIRE The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery April 18, 2023 Via ACCESSWIRE Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab March 29, 2023 Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD From Psycheceutical Bioscience, Inc. Via GlobeNewswire What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution March 29, 2023 By Faith Ashmore, Benzinga Via TheNewswire.com Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD March 21, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD March 01, 2023 By Julian Richard, Benzinga Via TheNewswire.com BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD February 17, 2023 Via Investor Brand Network Exposures Product Safety Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD February 15, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD February 02, 2023 Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD From Psycheceutical Bioscience, Inc. Via GlobeNewswire Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD January 26, 2023 Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) From Psycheceutical Bioscience, Inc. Via GlobeNewswire Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer January 10, 2023 Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics From Psycheceutical Bioscience, Inc. Via GlobeNewswire Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director November 29, 2022 Dr. Logsdon’s expertise to help guide the company’s further research and development for its patented drug-delivery technology From Psycheceutical Bioscience, Inc. Via GlobeNewswire Psycheceutical Bioscience, Inc. Announces Medical Advisory Board October 18, 2022 To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments From Psycheceutical Bioscience, Inc. Via GlobeNewswire Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council October 04, 2022 Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board From Psycheceutical Bioscience, Inc. Via GlobeNewswire Psycheceutical Completes Acquisition by Blue Water Ventures International January 20, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Blue Water Ventures International, Inc. Signs Non-Binding Letter of Intent to Acquire Psycheceutical, Inc. November 03, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Blue Water Ventures International and Partners Endurance Exploration Group Share Update on the Current 2021 Recovery Season of Steamboat Pulaski August 25, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire New Sonar Survey Discovers Large Unsalvaged Sections of SB Pulaski, 1838 June 23, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.